Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540993 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,734
- Enrollment target
NCT02540993 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 5,734 participants.
The verdict
NCT02540993, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,734 participants
- Enrollment target
Study Summary
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.
Interventions
- DRUG Placebo
- DRUG Finerenone (BAY94-8862)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,734 participants |
| Start Date | 2015-09-17 |
| Est. Completion | 2020-04-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02540993
The ClinicalTrials.gov registry entry for NCT02540993 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,734 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02540993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02540993 about?
NCT02540993 is a clinical study titled "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease". The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glo...
What is the current status of trial NCT02540993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,734 participants. The study started on 2015-09-17. Estimated completion is 2020-04-14.
What interventions are being tested in trial NCT02540993?
The interventions under investigation include: Placebo (DRUG), Finerenone (BAY94-8862) (DRUG).
Who is sponsoring clinical trial NCT02540993?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.